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Abstract
Background: Programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) inhibitors have quickly become standard of
care for patients with advanced non-small cell lung cancer and increasing numbers of other cancer types. In this
report, we discuss the clinical history, pathological evaluation, and genomic findings in a patient with metastatic
lung squamous cell cancer (SCC) who developed severe nivolumab-induced pneumonitis preceding durable clinical
remission after three doses of nivolumab.
Case presentation: A patient with chemotherapy-refractory, metastatic lung SCC developed symptomatic
pneumonitis by week 4 after nivolumab treatment, concurrently with onset of a potent antitumor response.
Despite discontinuation of nivolumab after three doses and the use of high dose oral corticosteroids for grade
3 pneumonitis, continued tumor response to a complete remission by 3 months was evident by radiographic
assessment. At the time of this submission, the patient has remained in clinical remission for 14 months. High
PD-L1 expression by immunohistochemistry staining was seen in intra-alveolar macrophages and viable tumor cells
in the pneumonitis and recurrent tumor specimens, respectively. Tumor genomic profiling by FoundationOne
targeted exome sequencing revealed a very high tumor mutation burden (TMB) corresponding to 95–96 percentile
in lung SCC, i.e., 87.4–91.0 and 82.9 mut/Mb, respectively, in pre- and post-nivolumab tumor specimens. Except for
one, the 13 functional genomic alterations remained the same in the diagnostic, recurrent, and post-treatment,
relapsed tumor specimens, suggesting that nivolumab reset the patient’s immune system against one or more
preexisting tumor-associated antigens (TAAs). One potential TAA candidate is telomerase reverse transcriptase
(TERT) in which an oncogenic promoter -146C>T mutation was detected. Human leukocyte antigen (HLA) typing
revealed HLA-A*0201 homozygosity, which is the prevalent HLA class I allele that has been used to develop
universal cancer vaccine targeting TERT-derived peptides.
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Conclusions: Nivolumab could quickly reset and sustain host immunity against preexisting TAA(s) in this
chemotherapy-refractory lung SCC patient. Further mechanistic studies are needed to characterize the effective
immune cells and define the HLA-restricted TAA(s) and the specific T cell receptor clones responsible for the potent
antitumor effect, with the aim of developing precision immunotherapy with improved effectiveness and safety.
Keywords: PD-1 inhibitor, Nivolumab, Cancer immunotherapy, Immune-related adverse event, Pneumonitis,
Complete remission, Tumor genomic profiling, Targeted exome sequencing, Tumor mutation burden, HLA
Background
First generation monoclonal antibodies against pro-
grammed death receptor 1 (PD-1) and its ligand 1 (PD-
L1) have quickly become standard of care in second-line
and more recently first-line treatment over chemother-
apy for patients with advanced non-small cell lung can-
cer (NSCLC) and an increasing number of other cancer
types [1–6]. Although these drugs are generally better
tolerated than chemotherapy, they are associated with
unique and variable immune-related adverse events
(irAEs) that if not recognized and treated promptly may
increase morbidity and rarely cause mortality [7, 8]. We
present a case of lung squamous cell cancer (SCC) with
complex tumor genomic alterations to highlight the
striking yet largely untapped potential of PD-1 inhibitor
therapy, as well as the need for further clinical and
translational research to optimize the safety and efficacy
of cancer immunotherapy.
Case presentation
A 67-year-old Caucasian man, former light smoker (4
pack-year, quit >45 years ago) with refractory metastatic
lung SCC, received nivolumab as third line systemic
therapy. He initially presented with SCC of unknown
primary with a 5.5-cm mass in the right axilla and me-
tastases in 4 of 28 regional lymph nodes. After complete
surgical resection, the patient received adjuvant chemo-
therapy with gemcitabine and paclitaxel for 2 cycles,
followed by adjuvant radiation to the right axilla and an
additional 2 cycles of gemcitabine and paclitaxel un-
eventfully over a 7-month period. Review of the CT scan
that was performed prior to adjuvant radiation to the
right axilla noted a new 10-mm nodule in the right
lower lobe (RLL) of the lung that had not been previ-
ously appreciated. In retrospect, the nodule was thought
to be the primary lung cancer. It was no longer present
on a subsequent scan after treatment. He tolerated
systemic chemotherapy relatively well but had grade 1
radiation pneumonitis in the right upper lobe (RUL) of
the lungs detected by fluorodeoxyglucose (FDG)-posi-
tron emission tomography (PET)-computed tomography
(CT) scan at completion of radiation. Unfortunately,
surveillance PET/CT scan 4 months after completion of
his last dose of chemotherapy revealed a right axillary
mass of 2.8 × 1.5 cm with maximum standardized uptake
values (SUVmax) of 3.8, a RLL lung nodule which had
undergone cavitation and growth, measuring 2.2 ×
2.7 cm with SUVmax of 6.5, and a new 5-mm lung nod-
ule in the left lower lobe (LLL). The radiation pneumon-
itis in the RUL had improved without any intervention.
Biopsy of the recurrent right axillary mass and RLL lung
mass confirmed recurrent, moderately differentiated
SCC of most likely lung primary by immunohistochem-
istry stains (p40: positive and TTF1: negative). Given the
patient was initially thought to have locally advanced
SCC of unknown primary, all these tumor specimens were
sent for comprehensive tumor genomic profiling by
FoundationOne (Foundation Medicine, Cambridge, MA)
(Table 1, first three columns). Available histopathological
and radiographic data were reviewed at our institutional
multidisciplinary thoracic oncology tumor board. Skin pri-
mary was not favored as cutaneous SCC rarely has distant
metastasis and the patient did not have any skin lesion.
Both the initial and recurrent tumors were present in the
RLL of the lung. Together with the morphological and
immunohistochemistry (IHC) evaluation, a diagnosis of
lung SCC with RLL primary and metastases to the right
axilla, mediastinum, and left lung was made.
The patient received docetaxel and an investigational
agent on a clinical trial for recurrent disease. Despite an
initial partial response after 2 cycles of treatment, the
patient had rapid tumor progression radiographically by
PET/CT scan after 6 cycles of treatment. He subse-
quently started on standard of care nivolumab at 3 mg/
kg intravenously every 2 weeks based on CheckMate-
057 [9]. The patient reported increasing dyspnea on
exertion (DOE) and fatigue during his clinic visit for
pre-cycle 3 evaluation at week 4 day 3 (i.e., cycle 2 day
10) (Fig. 1A). He denied any productive cough, fever, or
night sweats. Chest x-ray on the same day revealed no
acute event although it was difficult to compare the
complex lung lesions to those on the prior PET and CT
scans. The patient proceeded with his third dose of
nivolumab at week 5 as planned.
Due to worsening DOE, a follow-up PET/CT scan at
week 6.5 was performed (Fig. 1B, b and c compared to
a), revealing: (1) interval development of a moderate to
large right pleural effusion with adjacent compressive
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Mutation allele frequency (MAF) (%)
TERT promoter -146C>T 6% 22% 35% 47%
PIK3CA Q661K 7% 24% 18% 23%
ARID2 R542a 6% 22% 27% 30%
CDC73 G28a 9%
CDKN2A A100V 11% 40% 48% 47%
CDKN2A R58a 12% 39% 46% 49%
FANCC E539K 8% 21% 28% 29%
FAT1 N126fsa20 3% 22% 24% 24%
NOTCH1 splice site 5639-1G>A 18% 35% 40% 35%
PTCH1 P253L 3% 9% 15% 13%
SMAD4 Q180a 11% 25% 36% 37%
SPEN S346F 10% 26% 17% 16%
TP53 Q317a 2% 9% 10% 14%
TP53 Y163H 14% 37% 47% 44%
Number of functional genomic alterations 13 14 13 13
TMB (mut/Mb) 70.3 91.0 87.4 82.9
TMB percentile in lung SCC 98.8% 99.1% 99.1% 99.0%
aTruncated gene
fs frame shift, mut/Mb mutations per megabase
Fig. 1 Summary of treatment and monitoring tumor response. A Various interventions that the patient received. Arrowheads indicate time points
for each intervention. B (a–e) PET/CT or chest CT images for lung lesions before and after nivolumab. Radiologic response to nivolumab was first
noted at the onset of pneumonitis as multiple ground-glass opacities surrounded by consolidations of air bronchograms in bilateral lungs on
restaging PET/CT obtained at 6.5 weeks after nivolumab treatment. Subsequent CT scans showed resolution of pneumonitis and complete
remission of tumor at 13 weeks
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atelectasis, (2) significant increase in the surrounding
FDG activity in the preexisting large cavitary lesion in
the RLL, and (3) increased RLL consolidation with dif-
fuse FDG activity. It was unclear if the findings in the
RLL represented pneumonia, tumor progression, or drug
reaction. Interestingly, excluding these lung parenchymal
findings, there was significant decrease in the FDG activ-
ity and size of known tumors in the bilateral axillary and
mediastinal nodes (red arrows in Fig. 1B, b).
The patient was briefly admitted for possible severe
pneumonia and received empiric intravenous antibiotics.
He was discharged on oral antibiotics after all cultures
were negative for infection. However, the patient’s DOE
and fatigue did not improve and pneumonitis developed
in the LLL of the lung on chest CT scan (Fig. 1B, d). A
diagnostic bronchoscopy was performed approximately
4 weeks later, which revealed no evidence of infection
and two different pathologic lesions, i.e., organizing pneu-
monia in the right middle lobe (RML) (Fig. 2a) and exten-
sive endobronchial, moderately differentiated SCC tumors
in the RLL bronchus (Fig. 2b), which were debrided from
the RLL bronchus with a cryoprobe. Although the patient
had received two lines of chemotherapy (gemcitabine and
paclitaxel combination and docetaxel) in the prior year
with the last dose of chemotherapy that was more than
2 months ago, there was no distinct tumor necrosis or
treatment effect noted. There was focal inflammation
within the tumor but no distinct tumor cell reaction to
the inflammation (Fig. 2a). These findings suggest freshly
growing recurrent tumors in the RLL. Conversely, there
was no visible tumor seen in the RML and transbronchial
biopsy revealed alveolar parenchyma with fibroblast foci,
mild collagen expansion of alveolar septa, and non-
specific chronic inflammation (Fig. 2b). These features as
well as the patient’s clinical course suggested the diagnosis
of nivolumab-induced organizing pneumonia. We further
determined the PD-L1 expression on these specimens
by the FDA-approved IHC assay (PD-L1 22C3 IHC
pharmDx, Dako—Agilent Technologies). We found
PD-L1-positive cells infiltrating in the RML specimen
were predominantly intra-alveolar macrophages (Fig. 2c),
which may have contributed to the development of pneu-
monitis. There was insufficient normal lung tissue present
in this specimen for determining if PD-L1 expression on
normal lung tissue may also have contributed to the devel-
opment of site-specific pneumonitis. In contrast, 90% of
viable tumor cells in the RLL had high PD-L1 expression,
i.e., tumor proportion score (TPS) ≥50% with partial and
complete cell membrane staining (Fig. 2d).
Immediately after the initiation of prednisone at
60 mg per day, the patient had symptomatic improve-
ments with decreased DOE and chest tightness and in-
creased energy and exercise tolerance. Chest CT scan
about 2 weeks later (i.e., by week 13) revealed dramatic
improvement in pneumonitis (Fig. 1B, e). The patient
felt that he was nearly back to baseline 3 weeks later. He
had a “flare” of pneumonitis symptoms when steroids
were quickly tapered off, and subsequently improved
with re-initiation of steroids with a slow taper over
2 months. Despite treatment being discontinued after
three doses of nivolumab, continued tumor response
to a complete remission between week 5 and week 13
Fig. 2 Histological assessment of different lung pathologies. Hematoxylin and eosin staining revealed organizing pneumonia with fibroblast plugs
and inflammatory cells in the RML (a), and moderately differentiated squamous cell carcinoma in the RLL (b). Magnification, ×20. IHC staining for
PD‐L1 expression shows the presence of PD-L1 positive intra-alveolar macrophages in the RML (c) and strongly positive PD-L1 expression on the
surface of 90% of viable tumor cells (TPS ≥50%) (d). Magnification, ×100
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(i.e., ~3 months) was evident by radiographic assess-
ment. At the last follow-up before the submission of
this report, the patient has remained in clinical remis-
sion for 14 months.
The complex diagnostic challenges encountered in this
case lead to tumor genomic profiling analysis of four
tumor specimens by FoundationOne assay obtained at
initial diagnosis, tumor recurrence, and pneumonitis/
tumor progression (Fig. 3 and Table 1), a clinical strategy
that is not routinely employed for patients with ad-
vanced SCC with no driver mutations. We found that all
tumor specimens from this patient had a very high
tumor mutation burden (TMB) at 87.4–91.0 and
82.9 mut/Mb in the pre- and post-nivolumab tumor
specimens, respectively, corresponding to the 95–96
percentile of TMB in lung SCC (Table 1).
Discussion
The clinical characteristics, radiographic patterns, and
treatment course of PD-1 inhibitor-related pneumonitis
are quite variable [8, 10, 11]. A recent systematic review
and meta-analysis suggests that the overall incidence of
pneumonitis during PD-1 inhibitor monotherapy was
2.7% (95%CI, 1.9–3.6%) for all-grade and 0.8% (95%CI, 0.4–
1.2%) for grade 3 or higher pneumonitis. The incidence was
higher in NSCLC for all-grade (4.1 vs 1.6%; P = 0.002) and
grade 3 or higher (1.8 vs 0.2%; P < 0.001) pneumonitis com-
pared to melanoma [11]. The incidence of pneumonitis was
more frequent during combination therapy than monother-
apy for all-grade (6.6 vs 1.6%; P < 0.001) and grade 3 or
higher (1.5 vs 0.2%; P = 0.001) pneumonitis [11]. The
median time from therapy initiation to pneumonitis was
2.6 months, although it could occur after one or two doses
of a PD-1/PD-L1 inhibitor [11]. Variable clinicopathological
factors, such as preexisting lung damage due to tumor
burden, smoking, chronic obstructive pulmonary dis-
ease, pulmonary fibrosis, and variable expression of
PD-L1 on normal lung tissues, have all been associated
with a higher incidence of pneumonitis in NSCLC
patients compared to other tumor types. However, the
implicated factors are highly variable for individual pa-
tients [10]. Our patient had grade 1 radiation-induced
pneumonitis in the RUL after receiving radiation to the
right axilla, which was unlikely to have contributed to
the development of grade 3 pneumonitis present in the
RLL and LLL. We postulated that the infiltration of
PD-L1-positive macrophages played a role in the distri-
bution and severity of pneumonitis in the RML and
potentially other lung parenchymal areas. Our finding
suggests macrophage-mediated inflammatory responses
may have contributed to the pathogenesis of pneumon-
itis in this area. Early recognition and prompt initiation
of high dose, systemic corticosteroids and supportive
care in our patient resulted in resolution of pneumon-
itis without compromise of the antitumor effect. It is
unlikely that different clones of PD-1+ CD8+ T cells
might have mediated antitumor effect and/or irAE
(pneumonitis here) [12], although we could not entirely
rule out the expression of PD-L1 on normal lung epithelial
cells and other immune regulators in the tumor micro-
environment (TME) due to the small size of available
tissue specimen obtained by transbronchial fine-needle as-
piration. Further mechanistic studies on more cases are
needed to fully understand the underlying mechanisms
and develop clinical guideline for evaluation and manage-
ment of PD-1/PD-L1 inhibitor-induced pneumonitis.
Fig. 3 Comparison of functional genomic alterations by FoundationOne assay. Graphic comparison of MAF% for each functional genomic
alteration detected by FoundationOne targeted exome sequencing assay in the initial (column A), recurrent and metastatic (columns B and C),
and post-treatment, relapsed tumor (column D)
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The patient’s tumor has several molecular characteris-
tics that have been associated with a favorable clinical
response to PD-1 inhibitors. First, the majority of post-
nivolumab viable tumor cells stained highly positive
(TPS ≥50%) for PD-L1 protein expression by IHC
(Fig. 2d). Second, all tumor specimens from this patient
had a very high TMB (Table 1). TMB was calculated by
counting somatic genomic alterations detected per
megabase of the coding region target territory of the
FoundationOne test (currently 1.11 Mb for targeted ex-
ome sequencing of 315 oncogenes and tumor suppressor
genes; Foundation Medicine, Cambridge, MA, USA),
after filtering to remove known somatic and deleterious
mutations as described previously [13, 14]. High TMB
(>16 mut/Mb) by FoundationOne has been independ-
ently associated with improved PFS and OS in patients
with advanced NSCLC who had received atezolizumab
and other PD-1 or PD-L1 inhibitors [15, 16]. Although
restricting to the FoundationOne capture regions signifi-
cantly reduced the total number of genomic alterations
detected, the whole exome and FoundationOne targeted
exome sequencing counts were highly correlated using
The Cancer Genome Atlas (TCGA) bladder urothelial
carcinoma exome-sequencing database [14]. Except for
one mutation (CDC73 G28*), 13 “functional” genomic
alterations, which are defined as known or likely onco-
genic genomic alterations, detected in the post-treatment,
relapsed tumor (column D) were identical to those of the
initial (column A) and recurrent metastatic (columns B
and C) tumors. Of note, the mutation allele frequency
(MAF) of the identified genomic mutations was usually
higher in the recurrent (columns B and C) and progressive
(column D) tumors than those of the initial tumor (col-
umn A) (Fig. 3). We believe the high MAFs were mainly
driven by the fraction of tumor present in the biopsy
specimens. These data suggest that it was unlikely that a
new neoantigen or tumor-associated antigen (TAA) had
emerged in the relapsed tumor compared to the primary
or recurrent metastatic tumors in this patient. This
phenomenon is quite different from oncogene-driven tu-
mors where stepwise, somatic-cell mutations with sequen-
tial, subclonal selections occur during cancer progression
and the development of acquired resistance to molecularly
targeted therapy [17, 18]. Third, all tumors harbored a
PIK3CA Q661K mutation and mutations in several DNA
damage response genes (Table 1) that have been associ-
ated with increased clinical responses to PD-1 or PD-L1
inhibitors [19–21]. Fourth, among all the functional gen-
omic alterations detected, telomerase reverse transcriptase
(TERT or hTERT) promoter -146C>T mutation had in-
crementally increased in MAF% over time (Fig. 3 and
Table 1), which could serve as a TAA. Several therapeutic
approaches targeting TERT are under development,
including immunotherapies utilizing TERT as a TAA,
antisense oligonucleotide- or peptide-based therapies, and
TERT promoter-directed cytotoxic molecules [22, 23]. We
do not know if whole exome sequencing could identify
additional TAA candidates. Further exploration and valid-
ation of these molecular biomarkers and potential TAA(s)
is warranted.
Discontinuation of nivolumab was recommended in
our patient due to the presence of grade 3 pneumonitis.
Luckily, at the diagnosis of pneumonitis at 4–5 weeks
after initiating nivolumab treatment, we observed radio-
graphic responses of existing tumors (Fig. 1), suggesting
the rapid activation of presumably PD-1+, tumor-
specific, CD8+ T cells. These potent CD8+ T cells were
able to eradicate all established and newly formed
biopsy-proven tumors in the RLL by ~3 months. Thus,
radiographic evaluation alone did not assess the func-
tional status of host immunity against cancer in our pa-
tient after cancer immunotherapy. The continued and
sustained antitumor response in our patient beyond a
year after discontinuing nivolumab challenges the
current clinical recommendation of continuing PD-L/
PD-L1 treatment for tumor progression for 2 years. Cur-
rently, the patient is under radiographic surveillance
every 3–4 months as standard of care for patients with
metastatic NSCLC. Moving forward, a noninvasive bio-
marker assay that can evaluate the status of host
immunity against tumor should be developed to evaluate
or monitor the status of immune function in cancer pa-
tients who have responded to PD-1/PD-L1 inhibitor
therapy [20].
Late tumor relapse has been reported for five ad-
vanced melanoma patients enrolled in the pivotal phase
I study [24], who were retreated at their originally
assigned dose and achieved durable disease control (one
had a complete response) over time and were alive at
5 years [25]. Should our patient have tumor recurrence,
the efficacy and safety of using nivolumab or another
PD-1/PD-L1 inhibitor is unknown. There is a critical
need to understand the mechanisms underlying the ex-
ceptional tumor response and treatment-related pneu-
monitis to guide subsequent clinical management of this
patient, ideally before his tumor recurs. In this patient,
rapid onset of effector T cell activation and tumor
response against the preexisting tumors (red arrows in
Fig. 1B, b) was noted when radiographic assessment was
done for evaluating severe pneumonitis. But this im-
mune response was not sufficient to eradicate all tumors
or stop the new tumor growth in the RML at that time
(Figs. 1B, b and 2b). Despite discontinuation of further
treatment, radiographic tumor remission in this patient
with chemotherapy-refractory, metastatic lung SCC was
achieved by week 13 (i.e., ~3 months) and maintained at
14 months after the last dose of nivolumab (Fig. 1B, e).
Of interest, the antitumor effect of nivolumab was also
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not compromised by the two lines of cytotoxic chemo-
therapy within 1 year immediately prior to nivolumab
treatment [9, 26]. Consistent with the Chen hypothesis
[27–30], nivolumab likely elicited exceptional tumor re-
sponse in this patient by resetting (or “reestablishing or
normalizing”) host immunity against the tumor. Further
analysis of clonal expansion of T cell receptor and B cell
receptor repertoires in post-nivolumab lymphocytes and
identifying TAA could help to prove this assumption. To
elicit cytolysis of tumor cells, effector T cells rely on
tumor expression of target antigens in a human
leukocyte antigen (HLA)-restricted manner that could
be predicted using experimental and mathematical
models [31, 32]. High resolution HLA typing revealed
homozygous HLA-A*0201 allele (Table 2), which is the
globally prevalent HLA class I allele that has been used
to study cancer vaccines for years and recently to de-
velop universal cancer vaccine targeting TERT-derived
peptides [32].
Our study has several limitations. First, we did not
understand the mechanisms of immune evasion in this
patient. Second, we could not identify and characterize
the effector immune cells, cytokines, and chemokines
that are responsible for the potent and durable antitu-
mor effect in this patient. Identifying the specific T cell
receptor (TCR)(s) and HLA-restricted TAA(s) using ser-
ial tumor and blood specimens obtained before, during,
and after discontinuation of nivolumab in this patient
would help to understand the T cell responses that are
responsible for such an exceptional antitumor response
and could help design a personalized cancer vaccine or
adoptive T cell therapy to improve the efficacy and safety
of cancer immunotherapy should our patient have tumor
recurrence. Third, we could not characterize the expres-
sion of tumor cells and immune cells in the TME in
more than two areas of the lung that were responsible
for the variable tumor responses and pneumonitis.
Fourth, we did not determine whether or not other gen-
etic factors, such as genetic polymorphisms in cytokine
genes and pharmacogenetics, were involved in modulat-
ing the immune responses in our patient [33]. As PD-1/
PD-L1 inhibitors have been rapidly integrated into
standard of care for NSCLC and increasing numbers of
other cancer types [34–38], more mechanistic studies
are needed to understand the underlying mechanisms of
tumor response and resistance. Also needed is the devel-
opment of biomarkers, not only to predict treatment
effects but also potentially fatal toxicities.
Conclusions
We report our multidisciplinary clinical experience and
molecular and immune biomarker studies in a patient
with refractory, lung SCC who developed grade 3 pneu-
monitis after three doses of nivolumab monotherapy
concurrent with the onset of a potent antitumor re-
sponse that led to a durable clinical remission. We found
that high PD-L1 expression by IHC staining was seen in
intra-alveolar macrophages and viable tumor cells in the
pneumonitis and recurrent tumor specimens, respect-
ively. The prompt recognition and institution of oral
steroids appeared to have prevented serious morbidity and
potential mortality from pneumonitis without compromis-
ing the remarkable antitumor effect. Despite discontinu-
ation of treatment after only three doses of nivolumab,
continued tumor response to a complete remission at
~3 months evident by radiographic assessments has been
maintained up to the time of submission of this report at
14-month follow-up. To the best of our knowledge, this is
the first report of comprehensive tumor genomic profiling
on serial tumor specimens from a lung SCC patient who
has had an exceptional clinical response to nivolumab.
There are critical needs (1) to delineate the mechanisms
underlying exceptional tumor responses and severe tissue-
specific, immune-mediated toxicities, (2) to develop non-
invasive assay(s) for evaluating the status of antitumor
host immunity, and (3) to develop personalized immuno-
therapy strategies to improve the effectiveness and safety
of cancer immunotherapy.
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